[Synthesis and biological properties of α-thymidine 5'-aryl phosphonates]. 2013

M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova

The interaction of CDI-activated diethyl phosphonoacetate with methyl 4-aminobenzoat or 3,5-difluoromethylphenylamine followed by treatment with Me3SiBr in DMF led to N-aryl aminocarbonylmethyl phosphonates and their ethyl esters. Their coupling with 3'-acetyl-α-thymidine followed by removal of the acetyl groups gave (α-D-thymidine-5'-il) N-[4-(methoxycarbonyl-, aminocarbonyl- and carboxy)phenyl]-aminocarbonylmethyl phosphonates, (α-D-thymidine-5'-il)-[3,5-bis(trifluoromethyl)phenylaminocarbonyl]methyl phosphonate and their ethyl esters. The phosphonates were stable in different conditions, low cytotoxic (in Vero and K562 cells) and were able to penetrate into K562 cells. The only ethyl ester of (α-D-thymidine-5'-il) N-[4-(methoxycarbonyl)phenyl]-aminocarbonylmethyl phosphonate in high concentration (200 μg/mL) inhibited in vitro the growth of laboratory sensitive strain of Mycobacterium tuberculosis H37Rv.

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D013942 Thymine Nucleotides Phosphate esters of THYMIDINE in N-glycosidic linkage with ribose or deoxyribose, as occurs in nucleic acids. (From Dorland, 28th ed, p1154) Thymidine Phosphates,Nucleotides, Thymine,Phosphates, Thymidine
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses

Related Publications

M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
May 2024, Chemical science,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
March 2006, Bioorganic & medicinal chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
March 2015, Chemical communications (Cambridge, England),
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
March 1996, Journal of medicinal chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
May 1974, Journal of medicinal chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
July 2015, European journal of medicinal chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
January 2019, Molecules (Basel, Switzerland),
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
August 2018, Bioorganic & medicinal chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
February 2012, Organic & biomolecular chemistry,
M A Ivanov, and I L Karpenko, and L N Chernousova, and S N Andreevskaia, and T G Smirnova, and L A Aleksandrova
July 2014, Journal of the American Chemical Society,
Copied contents to your clipboard!